Under the three-year contract, Dendrite will be responsible for ensuring that Astellas' 500-strong US sales force will remain compliant with Prescription Drug Marketing Act (PDMA) requirements.
As Astellas - the US affiliate of Tokyo-based Astellas Pharm - continues to grow, its need for a sophisticated accountability and compliance solution has also grown.
"Dendrite came out on top in our evaluation of companies that could meet our immediate and long term needs for sample management and compliance," said Kathy Pettinato, associate director of Sampling Operations at Astellas.
Dendrite will manage Astellas' compliance requirements using its proprietary Sample Compliance Solutions software, designed to decrease the administrative burden associated with the accountability of drug samples.
Specific services will include reconciliation, web-based reporting and trending, inventory and auditing, as well as sales representative closeouts.